- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma ; volume:12 ; number:3 ; year:2019 ; pages:872-879
Case reports in oncology ; 12, Heft 3 (2019), 872-879
- Creator
-
Bjursten, Sara
Vannas, Christoffer
Filges, Stefan
Puls, Florian
Pandita, Ankur
Fagman, Henrik
Ståhlberg, Anders
Levin, Max
- DOI
-
10.1159/000504291
- URN
-
urn:nbn:de:101:1-2020011600134526987782
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bjursten, Sara
- Vannas, Christoffer
- Filges, Stefan
- Puls, Florian
- Pandita, Ankur
- Fagman, Henrik
- Ståhlberg, Anders
- Levin, Max
Other Objects (12)
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors